Back to Studies
P1059 / Phase I Trial of Recombinant Vaccines in HIV+ Young Adults
A Phase I Open Label Study to Evaluate the Safety & Tolerability of Recombinant Vaccines in HIV-Infected Young Adults with Good Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy
Study Status
Concluded
DAIDS Number
10051
IND Number
BB 12268
Primary Protocol Team Members
Summary
P1059 was Phase I, open-label study among HIV-infected youth receiving treatment in the United States. The study was designed to determine the safety and tolerability of recombinant MVA and Fowlpox HIV-1 vaccines in HIV-1-infected young adults with good control of HIV replication (HIV RNA < 100 copies/mL for 6 months) on stable antiretroviral therapy.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...